<DOC>
	<DOCNO>NCT03051373</DOCNO>
	<brief_summary>Gemcitabine plus cisplatin study used anticancer agent patient local advance and/or metastatic transitional cell carcinoma urothelial tract even clinical benefit survival remain limited . The purpose study test randomize trial enrol patient compare efficacy safety nab-paclitaxel plus S-1 Gemcitabine plus cisplatin , order determine promise agent first line treatment advance and/or metastatic transitional cell carcinoma urothelial tract .</brief_summary>
	<brief_title>Phase 2 Trial Nab-paclitaxel Plus S-1 v Gemcitabine Plus Cisplatin 1-line Chemotherapy Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma Urothelial Tract</brief_title>
	<detailed_description>Gemcitabine plus cisplatin study used anticancer agent patient local advance and/or metastatic transitional cell carcinoma urothelial tract even clinical benefit survival remain limited . The purpose study test randomize trial enrol patient compare efficacy safety nab-paclitaxel plus S-1 Gemcitabine plus cisplatin , order determine promise agent first line treatment advance and/or metastatic transitional cell carcinoma urothelial tract .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Signed informedconsent form . 2 . Man woman age 18 year 70 year . 3 . Histologically confirm unresectable locally advanced metastatic transitional cell carcinoma , occur renal pelvis , ureter , urinary bladder urethra : unresectable stage T34 tumor ; lymph node metastasis ; distance metastasis . 4 . Patients mixed histology may enrol proportion transitional cell carcinoma predominant component ( &gt; 50 % histopathology sample ) . 5 . Patient without prior anticancer therapy , except radical excision . Prior adjuvant therapy allow , document relapse intervention &gt; 12 month since completion last adjuvant therapy . 6 . At least one measurable tumor lesion ( measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) criteria v1.1 ) , measurable tumor receive local therapy ( e.g . radiotherapy cryotherapy ) . 7 . Eastern Cooperative Oncology Group ( ECOG ) 01 , progression within 2 week enter trial , life expectation le 12 week . 8 . Patients must receive previous chemotherapy investigational therapy treatment metastatic disease . Prior treatment 5fluorouracil gemcitabine administer radiation sensitizer adjuvant setting allow , provide least 6 month elapse since completion last dose linger toxicity present . 9 . Females childbearing potential must negative serum pregnancy test must breastfeed first dose . Male also need contraception . 1 . Patients accept therapy blow : Patients receive prior systemic therapy , include chemotherapy , biotherapy , immunotherapy experimental therapy , except adjuvant neoadjuvant therapy . Undergo major surgery ( except revascularization ) within 4 week prior first dose . Undergo radiotherapy 30 % marrow , large field irradiation within 4 week prior first dose . Patients take ( ca n't stop within 1 week prior first dose ) certain drug herbal supplement , know inhibitor inducer cytochrome P450 ( CYP ) 3A4 . Other anticancer therapy . The interval discontinuation investigational agent le 5 T1/2 drug . Patients aware receive similar therapy . 2 . Concurrent past history another malignancy , need therapy within 2 year first dose . 3 . Any unresolved AE grade &gt; 1 ( CTCAE ) previous systemic therapy ( e.g . adjuvant chemotherapy ) entry trial , except alopecia grade 2 neuropathy induce former chemotherapy . 4 . Patients symptomatic central nervous system ( CNS ) metastasis . 5 . Patients unstable serious concurrent medical condition exclude . The researcher evaluate patient suitable participation study . Patients active infection , limited HBV , HCV , HIV . 6 . Uncontrollable nausea , vomit , chronic gastrointestinal disorder lead unable swallow drug , may affect fully absorption S1 . 7 . Patients active cardiac disease include follow : In rest state , average correction QTc &gt; 470 msec mean value 3 time screen ECGs , data come outpatient screening period . Any clinically significant abnormal ECG form , example , complete leave bundle branch block , 3degree atrioventricular block , 2degree atrioventricular block , PR interval &gt; 250 msec . Any factor may increase risk QTc prolongation arrhythmic event . 8 . Marrow function abnormality organ dysfunction , reach follow laboratory value : ANC &lt; 1.5 x 109/L Platelets &lt; 100 x 109/L Hemoglobin &lt; 9.0 g/dL Alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) without liver metastasis ; ALT &gt; 5 x ULN , liver metastasis present . Aspartate aminotransferase ( AST ) &gt; 2.5 ULN , without liver metastasis ; AST &gt; 5 x ULN , liver metastasis present . Serum total bilirubin &gt; 1.5 x ULN without liver metastasis ; total bilirubin &gt; 3.0 x ULN patient well document Gilbert syndrome liver metastasis . Serum creatinine &gt; 1.5 x ULN 24hour clearance &lt; 50 mL/min ( measure value , calculate CockcroftGault formula ) time ; creatinine &gt; 1.5 x ULN , 24hour clearance need confirm . 9 . Patients unwilling unable abide study protocol , prohibition requirement . Patient take part study judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>